CPT-11: Farmaco Originale per il Cancro Colorettale Metastatico

Advanced Colorectal Cancer Meta-analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol, 10: 896–903, 1992.

Advanced Colorectal Cancer Meta-analysis Project: Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol, 10: 960–969, 1994.

Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol, 16: 301–308, 1998.

Haskell C.M. , Selch M.T. , Ramming K.P. : Colon and rectum. In: Haskel CM (Ed): Colon and rectum in cancer treatment (III ed), pp. 232–254, Saunders, Philadelphia, PA, 1990.

Creemers G.J. , Lund B. , Verwej J. : Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat. Rev., 20: 73–96, 1994.

Chen A.Y. , Liu L.F. : DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol, 34: 191–218, 1994.

Giovanella B.C. , Stehlin J.S. , Wall M.E. : DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science, 246: 1046–1048, 1989.

Shimada P. , Rothenberg M. , Hilsenbeck S.G. : Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor against human colony-forming units. Anticancer Drugs, 5: 20–26, 1994.

Chen A.Y. , Yu C. , Potmesil M. : Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res, 51: 6039–6044, 1991.

Wani M.C. , Ronman P.E. , Lindley J.T. , Wall M.E. : Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J Med Chem, 23: 554–560, 1980.

Sugimoto Y. , Tsukahara S. , Oh-Hara T. : Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res, 50: 6925–6930, 1990.

Tamura H. , Kohchi C. , Yamada R. : Molecular cloning of a cDNA topoisomerase I and identification of mutation sites. Nucleic Acids Res, 51: 1129–1136, 1991.

Rothenberg M.L. , Kuhn J.G. , Burris H.A. III : Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol, 11: 2194–2204, 1993.

De Forni M. , Bugat R. , Chabot G.G. : Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res, 54: 4347–4354, 1994.

Rowinsky E.K. , Grochow L.B. , Ettinger D.S. : Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1 -piperidino)-1 -piperidino]-carbonyloxy-camptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res, 54: 427–436, 1994.

Abigerges D. , Chabot G.G. , Armand J.P. : Phase I and pharmacokinetic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol, 13: 210–221, 1995.

Catimel G. , Chabot G.G. , Guastalla J.P. : Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol, 6: 133–140, 1995.

Gandia D. , Abigerges D. , Armand J.P. : CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol, 11: 196–197, 1993 (letter).

Chabot G.G. , Abigerges D. , Catimel G. : Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol, 6: 141–151, 1995.

Kaneda N. , Nagata H. , Furuta T. , Yokokura T. : Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res, 50: 1715–1720, 1990.

Shimada Y. , Yoshimo M. , Wakui A. : Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol, 11: 909–913, 1993.

Rothenberg M.L. , Eckardt J.E. , Kuhn J.G. : Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol, 14: 1128–1135, 1996.

Pitot H.C. , Wender D.B. , O'Connell M.J. : Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol, 15: 2910–2919, 1997.

Masuda S. , Fukuoka M. , Kusunoki Y. : A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol, 10: 1225–1229, 1992.

Von Hoff D.D. , Rothenberg M.L. , Pitot H.C. : Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): overall results of FDA-reviewed pilotai US clinical trials. J Clin Oncol, 16: 228a, 1997 (abs 803).

Rougier P. , Bugat R. , Douillard J.Y. : Phase II study of irinotecan in the treatment of advanced colorectal cancer in che motherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol, 15: 251–260, 1997.

Van Cutsem E. , Rougier P. , Droz J.P. : Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer (CRC) resistant to 5-FU. J Clin Oncol, 16: 268a, 1997 (abs 950).

Cunningham D. , Pyrrhönen S. , James R.D. : Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352: 1413–1418, 1998.

Rougier P. , Van Cutsem E. , Bajetta E. : Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 352: 1407–1412, 1998.

Conti J.A. , Kemeny N.E. , Saltz L.B. : Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol, 14: 709–715, 1996.

Pozzo C. , Pyrhönen S. , Bodrogi I. : A randomized phase II trial assessing irinotecan (IRI) and 5FU/folinic acid (LV), “Mayo regimen”, in first line palliative chemotherapy patients with metastatic colorectal cancer. Proc. ECCO 10, Eur J Cancer, 35: S71 (abstr 213), 1999.

Van Cutsem E. , Pozzo C. , Starkhammar H. : A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. Ann Oncol, 9: 1199–1204, 1998.

Saltz L.B. , Locker P.K. , Pirotta N. : Weekly irinotecan (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily × 5 LV/FU in patients with previously untreated metastatic colorectal cancer. Proc. ASCO, 18: 233a (abstr 898), 1999.

Douillard J.Y. , Cunningham D. , Roth A.D. : A randomized phase III trial comparing irinotecan (IRI) + 5FU/folinic acid (FA) to the same schedule of 5FU/FA in patients with metastatic colorectal cancer as front line chemotherapy. Proc. ASCO, 18: 233a (abstr 899), 1999.